On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

VSX2

visual system homeobox 2

Chromosome 14q24.3 Various HGNC:1975 Tier C
VSX2 14q24.3 p arm q arm 14

VSX2 is located on the long (q) arm of chromosome 14, at band 14q24.3. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 14 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

VSX2, also known as visual system homeobox 2, encodes a homeodomain-containing transcription factor that plays a fundamental role in ocular morphogenesis. The gene is located on chromosome 14 and produces a 361-amino-acid protein that regulates the developmental programme required for retinal and lens formation. During embryonic development, VSX2 coordinates the proliferation of retinal progenitor cells and determines whether these cells differentiate into specific neuronal populations or maintain their proliferative capacity. The protein's activity is particularly important during the second trimester of human pregnancy, when the basic architecture of the eye is established. Disruption of VSX2 function can result in severe congenital eye malformations that affect vision from birth.

What the gene does

The VSX2 protein functions as a sequence-specific DNA-binding transcription factor that activates or represses target genes involved in eye development. Through its homeodomain, the protein recognises and binds to specific DNA motifs in the regulatory regions of genes controlling retinal progenitor cell behaviour. VSX2 promotes the expression of genes that maintain cells in a proliferative, undifferentiated state whilst simultaneously suppressing genes that trigger premature differentiation into photoreceptors or other retinal cell types. This dual activity ensures that a sufficient population of progenitor cells is maintained throughout the critical developmental window. The protein also interacts with other transcription factors and chromatin-modifying complexes to fine-tune gene expression patterns. In the developing lens, VSX2 contributes to the differentiation of lens epithelial cells and the maintenance of lens transparency. Without functional VSX2, the balance between cell proliferation and differentiation is disrupted, leading to underdeveloped or malformed ocular structures.

Video: Genetics 101

Chromosome location

VSX2 is located on the long arm of chromosome 14 at position 24.3, designated as 14q24.3. The gene spans a relatively compact genomic region and contains five coding exons that are transcribed and spliced to produce the mature messenger RNA. This chromosomal location is not associated with any common structural rearrangements, though deletions encompassing the gene have been reported in individuals with complex developmental phenotypes.

Protein structure

The VSX2 protein comprises 361 amino acids organised into several distinct functional regions. Disordered regions span amino acids 1-28, 104-151, 262-300, and 313-361, providing structural flexibility that may facilitate interactions with regulatory partners. The homeodomain, located at amino acids 148-207, mediates DNA binding through a conserved three-helix structure that recognises specific nucleotide sequences. The CVC domain extends from amino acids 208-261 and is implicated in transcriptional activity and protein-protein interactions. An OAR motif occupies amino acids 304-317 and contributes to the protein's regulatory functions. The extensive disordered regions allow the protein to adopt multiple conformations depending on its binding partners and post-translational modifications.

Domain map · 361 amino acids
Homeobox (148-207)CVC (208-261)OAR (304-317)Homeobox148-207CVC208-261OAR304-3171~181361
Region - functional region
Domain - independent functional unit
Motif - short conserved sequence
🧬 Explore 3D structure on AlphaFold
UniProt:P58304Length:361 aaStructure:AlphaFold

Key variants

Pathogenic variants in VSX2 are predominantly loss-of-function changes, including nonsense mutations, frameshifts, and missense substitutions that disrupt the homeodomain structure or impair DNA-binding capacity. Both dominant and recessive inheritance patterns have been documented, with some variants exerting dominant-negative effects by producing proteins that interfere with wild-type VSX2 function. The severity of ocular phenotypes often correlates with the degree of functional impairment, ranging from isolated microphthalmia to complex anterior segment dysgenesis.

No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.

Associated conditions

VSX2 pathogenic variants are associated with a spectrum of congenital eye malformations. Microphthalmia, characterised by abnormally small eyes, represents one of the most common manifestations and can occur in isolation or alongside other ocular abnormalities. Bilateral congenital cataracts, in which lens opacities are present from birth, have been linked to specific VSX2 variants. Additional features may include coloboma, where portions of ocular tissue fail to close during development, and structural anomalies affecting the cornea, iris, or anterior chamber. The clinical presentation is variable, with some individuals experiencing severe bilateral involvement and others showing milder unilateral findings.

No condition pages are linked to this gene yet. This does not mean it has no associated conditions.

UK clinical status

VSX2 is included on several NHS Genomic Medicine Service gene panels reflecting its role in developmental eye disorders. The gene appears on the Anophthalmia or microphthalmia panel, the Bilateral congenital or childhood onset cataracts panel (R31), and the Ocular coloboma panel, all with green classification indicating strong evidence for clinical validity. VSX2 is also listed on the Retinal disorders panel (R32), the Structural eye disease panel (R36), and the Fetal anomalies panel (R21), supporting its use in prenatal and postnatal genetic testing for individuals with unexplained structural eye abnormalities. Inclusion in the DDG2P resource further underscores its relevance to developmental disorders. These panel memberships facilitate genetic diagnosis for affected individuals and carrier screening for families with a history of congenital eye conditions.

Frequently asked questions

What type of protein does VSX2 encode?

VSX2 encodes a homeodomain-containing transcription factor that binds to specific DNA sequences to regulate the expression of genes involved in eye development, particularly during retinal and lens formation.

Are VSX2 variants inherited?

VSX2 variants can be inherited in both autosomal dominant and autosomal recessive patterns, depending on the specific variant and its functional effect. Some individuals inherit pathogenic variants from affected parents, whilst others have de novo changes arising for the first time.

Why is VSX2 testing included in UK clinical panels?

VSX2 is included on multiple NHS gene panels for congenital eye conditions because pathogenic variants in the gene are an established cause of microphthalmia, congenital cataracts, and structural eye malformations that can be detected through genetic testing.

Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 17 April 2026. Content compiled from HGNC · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .